Development of "next generation" HIV therapies and tackling of HIV co-morbidities like hepatitis are among the HIV research priorities outlined in a new five-year strategic plan to guide NIH-funded research. The NIH Strategic Plan for HIV and HIV-Related Research covers 2021-2025 and outlines priorities and goals for coordination of HIV-related research across NIH, internationally and in the U.S. In fiscal year 2019, $3 billion in research funds were disseminated across NIH for such work.
The nearly 30 page plan includes context-setting infographics and data documenting: progress to date (see the ~40-year timeline): prevalence of HIV in the world (cases and new HIV infections--worldwide, 1.7 million people were newly infected in 2018); health outcomes (worldwide, HIV/AIDS deaths in 2018 declined 55% since the 2004 peak and 62% were on antiretroviral therapy); and HIV in the U.S. in terms of awareness of HIV status, engagement in care, and viral suppression.
Scientific priorities outlines in the plan include:
- reduce the Incidence of HIV
- address HIV-associated comorbidities, coinfections, and complications
- develop next-generation HIV therapies
- advance research toward a cure and
- support “cross-cutting areas"
Specifics are summarized in the below graphic.
The Plan also presents the following four strategic goals from the above scientific priorities.